Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isa-KPd for Relapsed/Refractory Multiple Myeloma
NCT04883242Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Jul 2021
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of isatuximab in multiple myeloma (MM), sponsored by University of Washington. Started Jul 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04883242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883242.